Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Evaluation of the Ezibreath in patients with chronic obstructive pulmonary disease

EF 2015-16

Résumé
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third leading cause of death by 2020. COPD accounts for the highest rate of hospital admissions among major chronic illnesses in Canada. Recent studies have provided strong evidence for an association between COPD and sleep disturbance. In fact, sleep-related complaints rank third in frequency, behind shortness of breath and fatigue in patients with COPD. Actigraphy is a non-invasive technique for monitoring sleep patterns in the comfort of a patient's own home and is an attractive alternative to complex and expensive laboratory based tests such as polysomnography (PSG). Agartee has developed an innovative actigraph specifically designed for patients with COPD. The device, known as the ""Ezibreath"", can measure many important variables that can be sent remotely to care providers to assist in the monitoring and management of patients with COPD. For example, the Ezibreath measures physical activity levels, heart rate, inhaler use, and sleep, among other variables. At this stage in the company's development, Agartee must optimize the accuracy of their algorithms before they can conduct validation studies. Agartee's first priority is to optimize their sleep algorithms. Accordingly, they will work with Dr. Jordan Guenette, an Assistant Professor at the University of British Columbia to test the Ezibreath during formal laboratory sleep testing. The study will simultaneously compare the Ezibreath to PSG in 12 clinically stable patients with moderate-to-severe COPD. They will then use the information from the gold standard PSG to refine their algorithms to optimize the accuracy of the Ezibreath.
Programme
Engage Grants Program
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
482758-2015
Name nom
Guenette, Jordan
Department département
Physical Therapy
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2015
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Evaluation of the Ezibreath in patients with chronic obstructive pulmonary disease
Keyword
NSERC
Application summary
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third leading cause of death by 2020. COPD accounts for the highest rate of hospital admissions among major chronic illnesses in Canada. Recent studies have provided strong evidence for an association between COPD and sleep disturbance. In fact, sleep-related complaints rank third in frequency, behind shortness of breath and fatigue in patients with COPD. Actigraphy is a non-invasive technique for monitoring sleep patterns in the comfort of a patient's own home and is an attractive alternative to complex and expensive laboratory based tests such as polysomnography (PSG). Agartee has developed an innovative actigraph specifically designed for patients with COPD. The device, known as the ""Ezibreath"", can measure many important variables that can be sent remotely to care providers to assist in the monitoring and management of patients with COPD. For example, the Ezibreath measures physical activity levels, heart rate, inhaler use, and sleep, among other variables. At this stage in the company's development, Agartee must optimize the accuracy of their algorithms before they can conduct validation studies. Agartee's first priority is to optimize their sleep algorithms. Accordingly, they will work with Dr. Jordan Guenette, an Assistant Professor at the University of British Columbia to test the Ezibreath during formal laboratory sleep testing. The study will simultaneously compare the Ezibreath to PSG in 12 clinically stable patients with moderate-to-severe COPD. They will then use the information from the gold standard PSG to refine their algorithms to optimize the accuracy of the Ezibreath.